Agenus Inc. (Nasdaq:AGEN) today published a new blog post on The Chairman's Blog, written by the company's Chairman and CEO, Dr. Garo Armen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Agenus Chairman and CEO, Dr. Garo Armen, writes about GSK's newly announced Phase 3 data for their RTS,S malaria vaccine candidate containing Agenus' QS-21 Stimulon adjuvant. He reflects on the companies' collaboration in their fight against malaria and results from additional QS-21-containing programs he expects to see in the near future. Read the full blog post on TheChairmansBlog.com (http://www.thechairmansblog.com/garo-armen/2013-10/agenus-and-gsk-work-together-in-the-fight-against-malaria.html).
Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products based on strong platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. For more information, please visit http://www.agenusbio.com/.
TheChairmansBlog.com is an exclusive, online media publication where publically and privatively held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. In addition to management`s insightful blog posts, TheChairmansBlog.com staff and aggregate partners contribute articles on finance, technology, health, and energy while providing updated market trends, news, and information.